MXPA05006994A - Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. - Google Patents

Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.

Info

Publication number
MXPA05006994A
MXPA05006994A MXPA05006994A MXPA05006994A MXPA05006994A MX PA05006994 A MXPA05006994 A MX PA05006994A MX PA05006994 A MXPA05006994 A MX PA05006994A MX PA05006994 A MXPA05006994 A MX PA05006994A MX PA05006994 A MXPA05006994 A MX PA05006994A
Authority
MX
Mexico
Prior art keywords
insulin
control
compositions
prevention
methods
Prior art date
Application number
MXPA05006994A
Other languages
English (en)
Spanish (es)
Inventor
R Henry Robert
Original Assignee
Diobex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex Inc filed Critical Diobex Inc
Publication of MXPA05006994A publication Critical patent/MXPA05006994A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MXPA05006994A 2002-12-27 2003-12-23 Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. MXPA05006994A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43673502P 2002-12-27 2002-12-27
US45497203P 2003-03-14 2003-03-14
US47034603P 2003-05-13 2003-05-13
PCT/US2003/041103 WO2004060387A1 (en) 2002-12-27 2003-12-23 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (1)

Publication Number Publication Date
MXPA05006994A true MXPA05006994A (es) 2005-10-18

Family

ID=32719167

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006994A MXPA05006994A (es) 2002-12-27 2003-12-23 Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.

Country Status (11)

Country Link
US (2) US7314859B2 (enExample)
EP (1) EP1578437A4 (enExample)
JP (1) JP2006514990A (enExample)
KR (1) KR20050086948A (enExample)
CN (1) CN1732012A (enExample)
AU (1) AU2003303634B2 (enExample)
CA (1) CA2509755A1 (enExample)
MX (1) MXPA05006994A (enExample)
NO (1) NO20053537L (enExample)
NZ (1) NZ541365A (enExample)
WO (1) WO2004060387A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808438B1 (en) 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1694386B1 (en) * 2003-12-05 2017-05-03 CareFusion 303, Inc. Patient-controlled analgesia with patient monitoring system
ZA200700708B (en) * 2004-06-29 2009-03-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
US8975227B2 (en) * 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN101534846B (zh) * 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
KR20100090692A (ko) * 2007-10-24 2010-08-16 맨카인드 코포레이션 활성제의 전달
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US10624577B2 (en) 2008-04-04 2020-04-21 Hygieia, Inc. Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
CN102016855A (zh) 2008-04-04 2011-04-13 海吉雅有限公司 用于优化患者的胰岛素剂量方案的装置
US9220456B2 (en) 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3153292A1 (en) 2008-06-13 2009-12-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US8992464B2 (en) 2008-11-11 2015-03-31 Hygieia, Inc. Apparatus and system for diabetes management
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9375529B2 (en) * 2009-09-02 2016-06-28 Becton, Dickinson And Company Extended use medical device
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2010099490A2 (en) 2009-02-27 2010-09-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2335755A1 (en) * 2009-12-17 2011-06-22 Sanofi-Aventis Deutschland GmbH Device and method for delivery of two or more drug agents
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
US20130053310A1 (en) 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN104093735B (zh) 2011-09-23 2018-07-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
FI3060276T3 (fi) * 2013-10-24 2023-06-07 Infuusiojärjestelmä monien lääkkeiden virheellisen kanavoinnin estämiseksi
EP4250313A3 (en) 2013-12-26 2023-11-22 Tandem Diabetes Care, Inc. Integration of infusion pump with remote electronic device
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
CN106029088A (zh) 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3050023B1 (en) 2014-10-27 2021-08-25 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2016308953B2 (en) 2015-08-20 2020-09-10 Glytec, Llc Diabetes management therapy advisor
CN107949374B (zh) * 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
ES2944544T3 (es) 2017-02-03 2023-06-22 Univ Vanderbilt Sistemas, composiciones y métodos para el tratamiento de la diabetes
WO2020130751A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
KR102495891B1 (ko) * 2020-03-04 2023-02-06 이오플로우(주) 약액 제어 주입 디바이스
EP4329812A1 (en) 2021-04-27 2024-03-06 Aardvark Therapeutics Inc. Combination of bitter receptor agonist and gut-signaling compound
GB202109087D0 (en) 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB748857A (en) 1952-12-16 1956-05-09 Nyegaard & Co As Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity
GB766994A (en) 1953-11-13 1957-01-30 Novo Terapeutisk Labortorium A Improved process in crystallization of insulin
GB766995A (en) 1953-11-14 1957-01-30 Novo Terapeutisk Labor As Improvements in or relating to the production of insulin crystals
US2902408A (en) 1957-09-12 1959-09-01 Organon Suspensions of drugs destined for injection and process for the preparation thereof
GB831907A (en) 1957-09-12 1960-04-06 Organon Labor Ltd Suspensions of drugs destined for injection and process for the preparation thereof
GB844434A (en) 1958-01-31 1960-08-10 Organon Nv Insulin preparations and process for preparing same
US3897551A (en) 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US4003379A (en) 1974-04-23 1977-01-18 Ellinwood Jr Everett H Apparatus and method for implanted self-powered medication dispensing
US4498843A (en) 1982-08-02 1985-02-12 Schneider Philip H Insulin infusion pump
IT1170375B (it) 1983-04-19 1987-06-03 Giuseppe Bombardieri Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
CA1196863A (en) 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4538616A (en) 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
DK27885A (da) 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
AT391998B (de) 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4879273A (en) 1987-05-22 1989-11-07 The Rockefeller University Glucagon homologs and therapeutic use thereof
NL8701644A (nl) 1987-07-13 1989-02-01 Cordis Europ Inrichting voor dosering in het lichaam van een vloeibaar materiaal.
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5101814A (en) 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
US5190041A (en) 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5527771A (en) 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
AU669110B2 (en) 1991-05-24 1996-05-30 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5814600A (en) 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
BR9407424A (pt) 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal
US5512468A (en) * 1993-11-12 1996-04-30 Stratagene Process of producing highly transformable bacterial cells and cells produced thereby
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
NL9401886A (nl) 1994-05-27 1996-01-02 Dsm Nv Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.
US5474552A (en) 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
JP4067058B2 (ja) 1995-03-10 2008-03-26 中村 敏一 Ｐｅｇ化ｈｇｆ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
BR9612359A (pt) 1995-12-27 1999-07-13 Genentech Inc Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
WO1997035560A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved echogenic liposome compositions
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
WO1998031383A1 (en) 1997-01-15 1998-07-23 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US5869062A (en) * 1997-05-27 1999-02-09 Oliver; Benjamin Skin treatment composition
US6093167A (en) 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US5919216A (en) 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
ATE233097T1 (de) 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
WO2000033866A1 (en) 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
US20020114829A1 (en) 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
US6360888B1 (en) 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6261280B1 (en) 1999-03-22 2001-07-17 Medtronic, Inc Method of obtaining a measure of blood glucose
HK1039065B (en) 1999-04-08 2004-04-16 Genentech, Inc. Composition based on oppositely-charged polypeptides
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CN1191273C (zh) 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6461331B1 (en) 1999-05-21 2002-10-08 Minimed Inc. Device and method for infusion of small molecule insulin mimetic materials
US20020026141A1 (en) 1999-11-04 2002-02-28 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
EP1280485A4 (en) 2000-02-29 2006-11-29 Zars Inc TRANSDERMAL STAMP FOR IMPROVED MEDICINE
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
JP2004508411A (ja) 2000-09-13 2004-03-18 プラエシス　ファーマシューティカルズ　インコーポレーテッド 持続的薬物送達のための医薬組成物
EP1333036B1 (en) 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
WO2002043566A2 (en) 2000-11-28 2002-06-06 Baum Martin G Devices and methods for treating low blood sugar levels
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US6656590B2 (en) * 2001-01-10 2003-12-02 Cabot Corporation Coated barium titanate-based particles and process
US6968743B2 (en) * 2001-01-22 2005-11-29 Integrated Sensing Systems, Inc. Implantable sensing device for physiologic parameter measurement
MXPA05005260A (es) 2002-11-18 2005-07-25 Pfizer Prod Inc Amidas ciclicas fluoradas que inhiben la dipeptidil peptidasa iv.
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1881786B1 (en) 2005-05-13 2017-11-15 Trustees of Boston University Fully automated control system for type 1 diabetes

Also Published As

Publication number Publication date
CA2509755A1 (en) 2004-07-22
US7314859B2 (en) 2008-01-01
KR20050086948A (ko) 2005-08-30
US20060160722A1 (en) 2006-07-20
EP1578437A1 (en) 2005-09-28
AU2003303634B2 (en) 2009-10-01
CN1732012A (zh) 2006-02-08
US20080096801A1 (en) 2008-04-24
JP2006514990A (ja) 2006-05-18
AU2003303634A1 (en) 2004-07-29
WO2004060387A1 (en) 2004-07-22
US7642232B2 (en) 2010-01-05
NO20053537L (no) 2005-08-26
EP1578437A4 (en) 2006-08-09
NZ541365A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
WO2007081824A3 (en) Fibrillation resistant proteins
BRPI0410972C1 (pt) método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
MXPA05003346A (es) Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico.
ATE369873T1 (de) Metabolische intervention mit glp-1 oder seinen biologisch aktiven analogen zur verbesserung der funktion des ischämischen und wiederdurchbluteten gehirns
TW200612987A (en) Combination treatment for non-hematologic malignancies
AP2001002146A0 (en) Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted idolealkanoic acids
JP2003521528A5 (enExample)
NO20003051L (no) Metode for administrering av AspB28-humant insulin
WO2011020319A8 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
SG149814A1 (en) Compositions and methods for treating diabetes
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
NO20070174L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
WO2007134326A3 (en) Methods for treating autoimmune diseases using a taci-ig fusion molecule
PT1965797E (pt) Redu??o de tonturas, um efeito secund?rio associado ? terapia com pirfenidona
MX2009007723A (es) Medicacion basada en exenatida y dalargina para el tratamiento de diabetes mellitus, su uso y modalidad de tratamiento.
CA2487362A1 (en) Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
GB0323979D0 (en) Therapeutic applications for c-peptide
TW200633720A (en) Medicinal composition for diabetic
TW200633702A (en) Medicinal composition containing fbpase inhibitor